MDS entities according to WHO-HAEM5 2022 and ICC 2022 classifications
| WHO-HAEM5 2022 . | ICC 2022 . |
|---|---|
| MDS with defining genetic abnormalities | |
| MDS with low blasts and isolated 5q deletion | MDS with del(5q) |
| MDS with low blasts and SF3B1 mutation∗ | MDS with mutated SF3B1 |
| MDS with biallelic TP53 inactivation | MDS with mutated TP53 |
| MDS, morphologically defined | |
| MDS with low blasts (<5% blasts; dysplasia is a prerequisite) | |
| MDS with low blasts and single-lineage dysplasia (MDS-LB-SLD) MDS with low blasts and multilineage dysplasia (MDS-LB-MLD) MDS with ring sideroblasts (MDS-RS) | MDS, NOS without dysplasia MDS, NOS with single lineage MDS, NOS with multilineage dysplasia |
| MDS, hypoplastic (<5% blasts) | |
| MDS with increased blasts (5% to <20% blasts) | |
| MDS-IB1 (5% to <10% blasts) MDS-IB2 (10% to <20% blasts) MDS with fibrosis (5% to <20% blasts) | MDS with excess blasts (5% to <10% blasts) MDS/AML (10% to <20% blasts) |
| WHO-HAEM5 2022 . | ICC 2022 . |
|---|---|
| MDS with defining genetic abnormalities | |
| MDS with low blasts and isolated 5q deletion | MDS with del(5q) |
| MDS with low blasts and SF3B1 mutation∗ | MDS with mutated SF3B1 |
| MDS with biallelic TP53 inactivation | MDS with mutated TP53 |
| MDS, morphologically defined | |
| MDS with low blasts (<5% blasts; dysplasia is a prerequisite) | |
| MDS with low blasts and single-lineage dysplasia (MDS-LB-SLD) MDS with low blasts and multilineage dysplasia (MDS-LB-MLD) MDS with ring sideroblasts (MDS-RS) | MDS, NOS without dysplasia MDS, NOS with single lineage MDS, NOS with multilineage dysplasia |
| MDS, hypoplastic (<5% blasts) | |
| MDS with increased blasts (5% to <20% blasts) | |
| MDS-IB1 (5% to <10% blasts) MDS-IB2 (10% to <20% blasts) MDS with fibrosis (5% to <20% blasts) | MDS with excess blasts (5% to <10% blasts) MDS/AML (10% to <20% blasts) |
IB1/2, increased blasts type 1/2; ICC, International Consensus Classification; LB, low blasts; MLD, multilineage dysplasia; NOS, not otherwise specified; RS, ring sideroblasts; SLD, single-lineage dysplasia.
When SF3B1 mutation analysis is not available and ring sideroblasts constitute ≥15% of erythroid precursors.